Here we review recent advances that identify a role for the central ghrelin signalling system in reward from both natural rewards (such as food) and artificial rewards (that include alcohol and drugs of abuse). Whereas ghrelin emerged as a stomach-derived hormone involved in energy balance, hunger and meal initiation via hypothalamic circuits, it now seems clear that it also has a role in motivated reward-driven behaviours via activation of the so-called "cholinergic-dopaminergic reward link". This reward link comprises a dopamine projection from the ventral tegmental area (VTA) to the nucleus accumbens together with a cholinergic input, arising primarily from the laterodorsal tegmental area. Ghrelin administration into the VTA or LDTg activates the "cholinergicdopaminergic" reward link, suggesting that ghrelin may increase the incentive value of motivated behaviours such as reward-seeking behaviour ("wanting" or "incentive motivation"). Further, direct injection of ghrelin into the brain ventricles or into the VTA
The central ghrelin signalling system
The "central ghrelin signalling system" is recognised as an important CNS target for the control of food intake (Wren et al. 2000) and energy balance (Lall et al. 2001; Tschöp et al. 2000) . Here we review the emerging concept that this system operates at the interface between neurobiological circuits involved in appetite and reward, increasing the incentive motivational value of both natural rewards (such as food) and artificial rewards (such as drugs of abuse).
We have coined the term "central ghrelin signalling system" to describe those CNS pathways that are directly or indirectly affected as a result of changes in stimulation of the known ghrelin receptor, GHS-R1A (growth hormone secretagogue receptor 1A).
GHS-R1A is present in a number of brain areas that include the hypothalamus, brainstem, tegmentum and hippocampus (Guan et al. 1997; Howard et al. 1996; Zigman et al. 2006) . By using the term "central ghrelin signalling system" we acknowledge the interesting pharmacology of this receptor, namely, that it has constitutive activity in the absence of ghrelin ligand (Holst et al. 2003; Holst and Schwartz 2004) . It follows that the activity of the receptor is not only dependent on the gut-brain signal provided by Page 4 of 38 A c c e p t e d M a n u s c r i p t 4 ghrelin. Indeed, the extent to which circulating ghrelin provides a physiological relevant signal for activation of this receptor, poses an interesting question. Moreover, the activity of GHS-R1A can be suppressed not only through pharmacological antagonism of ghrelin's effects but also independently of ghrelin (eg by using inverse agonists) (Mokrosinski and Holst 2010) . The "central ghrelin signalling system" emerges therefore as a key physiological system implicitly involved in the control of food intake and reward behaviour and also as a potential therapeutic target for the control of obesity as well as disorders of the reward system that include eating disorders and substance use disorders.
Interest in GHS-R1A as a therapeutic target began in the 1980s when a peptide called growth hormone-releasing peptide 6 (GHRP-6), the canonical member of a class of synthetic molecules known as growth hormone secretagogues (GHS), was identified as a potent stimulator of the hypothalamo-pituitary growth axis (Bowers et al. 1984) . The receptor for these ligands, GHS-R1A, was first described some years later by the group at Merck & Co (Howard et al. 1996) . Like many pharmaceutical companies at that time, they were developing potent agonists for improving growth hormone status. Given that growth hormone is lipolytic, there was little reason to link GHS-R1A to food intake or adiposity. The first hint that the central ghrelin signalling system is a relevant target for appetite and energy balance came from an unexpected observation in our group that the hypothalamic cells activated by GHRP-6 include not only the growth hormonereleasing hormone neurons in the arcuate nucleus but also the orexigenic NPY neurons in Page 5 of 38 A c c e p t e d M a n u s c r i p t 5 this region (Dickson et al. 1993; Dickson and Luckman 1997) . These NPY cells (that also coexpress another orexigenic peptide, agouti-related peptide) are now known to form a key component of the hypothalamic energy homeostatic circuits, receiving and integrating information also from many circulating satiety-regulating signals such as leptin and insulin (Cone et al. 2001; Hewson et al. 2002) .
The physiological role of ghrelin: from hunger to reward-seeking Soon after the discovery of ghrelin, the first endogenous ligand for GHS-R1A (Kojima et al. 1999) , it became clear that this receptor is also a potentially interesting target for controlling food intake and obesity. In rodents, acute injection of ghrelin, peripherally or centrally, induces a rapid orexigenic response (Asakawa et al. 2001; Wren et al. 2000) . It was also found that chronic stimulation of this receptor by ghrelin (Tschöp et al. 2000) or by synthetic growth hormone secretagogues (Lall et al. 2001 ) increases fat mass in rodents, by a mechanism that is independent of the hypothalamo-pituituary growth axis and, unexpectedly, did not appear to involve a hyperphagic response. Indeed, it has been proposed that ghrelin decreases fat utilization (Theander-Carrillo et al. 2006; Tschöp et al. 2000) , implying that the CNS circuits mediating ghrelin's acute orexigenic effects differ, at least in part, from those involved in fat accumulation. We noticed previously that ghrelin's orexigenic effects decline after a few days of repeated peripheral ghrelin injection (Dornonville de la Cour et al. 2005) . However, in another chronic study, in which rats received a 2 week infusion of ghrelin into the brain ventricles, we were surprised to detect a clear orexigenic response (Salomé et al. 2009 ), suggesting that under certain Page 6 of 38 A c c e p t e d M a n u s c r i p t 6 experimental/physiological conditions, the orexigenic ghrelin-responsive networks remain ghrelin-sensitive during chronic exposure.
Ghrelin levels increase pre-prandially (Cummings et al. 2001) and have been shown to correlate with hunger scores in healthy subjects (Cummings et al. 2004) indicating that, at least in normal physiology, acute changes of ghrelin may have a role in the decision to eat and/or serve as a circulating hunger hormone. Studies in rodents exploring the precise parenchymal targets for ghrelin's orexigenic effects have identified a number of candidate sites: orexigenic responses have been observed when injected into discrete brain areas that include the hypothalamus (arcuate nucleus, ventromedial nucleus, dorsomedial nucleus, paraventricular nucleus, lateral hypothalamus) (Olszewski et al. 2003a; Olszewski et al. 2003b; , the nucleus tractus solitarius of the brainstem (Faulconbridge et al. 2003) , the central nucleus of the amygdala (Olszewski et al. 2003) and mesolimbic reward areas (the ventral tegmental area (VTA) and nucleus accumbens (N.Acc) (Egecioglu et al. 2010; Naleid et al. 2005) . Activation of hypothalamic and brainstem areas could be of importance for ghrelin's effects on homeostatic feeding that is driven by metabolic need. However, ghrelin may also enhance non-homeostatic feeding by interacting with key reward systems (Egecioglu et al. 2010; Perello et al. 2010; Skibicka et al. 2011a; Skibicka et al. 2011b ). The reward system, specifically the mesolimbic dopamine system, mediates a state of well-being of natural and chemical reinforcers; it enhances motivation behaviours such as food-seeking and is involved in the development of addiction to drugs of abuse (Engel et al. 1988; Hansen et al. 1991 The identification of the reward circuits as a key target for ghrelin has therefore led to the unexpected discovery that the central ghrelin signalling system is required for reward induced by addictive drugs Kaur and Ryabinin 2010; Tessari et al. 2007; Wellman et al. 2005) as well as palatable food (Egecioglu et al. 2010; Perello et al. 2010; Skibicka et al. 2011a; Skibicka et al. 2011b ). The ghrelin receptor, GHS-R1A, has emerged therefore as a relevant therapeutic target for addictive behaviours.
The central ghrelin signalling system integrates with a key reward pathway
The mesolimbic dopamine pathway (Figure 1 (Guan et al. 1997; Zigman et al. 2006) , including a subpopulation of dopamine cells in this region (Abizaid et al. 2006) . Both central and intra-VTA administration of ghrelin induces an increase in accumbal dopamine release and also induces a locomotor stimulation (Jerlhag et al. 2006a; Jerlhag et al. 2007 ) as well as an increase in dopamine turnover in N.Acc (Abizaid et al. 2006) . Peripherally injected ghrelin also stimulates the mesolimbic dopamine system (Jerlhag 2008; Quarta et al. 2009) suggesting that peripherally produced ghrelin is able to access (or indirectly activate) the mesolimbic reward circuits. Interestingly, administration of a GHS-R1A antagonist into the VTA blocks the ability of ghrelin to increase food intake (Abizaid et al. 2006) and to release dopamine in the N.Acc suggesting that ghrelin activates GHS-R1A expressed on dopaminergic cell bodies in the VTA. Given that accumbal dopamine release appears to mediate the rewarding properties of incentives (eg food and alcohol) (Engel et al. 1988; Robinson and Berridge 1993; Wise and Bozarth 1987) , the collective data showing that ghrelin targets this dopamine system implicates GHS-R1A directly in the reward mechanism.
The mesolimbic dopamine system forms together with the cholinergic projection from the laterodorsal tegmental area (LDTg) to the VTA the cholinergic-dopaminergic reward link (Figure 1 ). This reward link is activated by natural as well as chemical reinforcers, as reviewed previously (Larsson and Engel 2004) . Involvement of this reward link in druginduced as well as natural reward has been implied, thus food as well as alcohol intake increases the ventral tegmental acetylcholine levels as well as accumbal dopamine Page 9 of 38 A c c e p t e d M a n u s c r i p t 9 levels (Hernandez and Hoebel 1988; Larsson et al. 2005; Rada et al. 2000) . GHS-R1A is expressed in the LDTg (Guan et al. 1997) , specifically on cholinergic cells (Dickson et al. 2010) , suggesting that ghrelin may have direct effects in this reward node. We have found that local administration of ghrelin into the LDTg activates parameters associated with reward, namely locomotor stimulation and accumbal dopamine release (Jerlhag et al. 2007 ). Moreover, these effects of ghrelin were blocked by peripheral or intra-VTA administration of an unselective nicotinic cholinergic antagonist, mecamylamine (Jerlhag et al. 2006a; Jerlhag et al. 2008) . Additionally, peripheral injection of mecamylamine has been shown to block the ability of ghrelin, locally administered into the VTA, to increase food intake (Dickson et al. 2010) . Collectively, these studies demonstrate that ghrelin activates the cholinergic-dopaminergic reward link and thereby may increase the incentive salience of motivated behaviours such as reward seeking. Further, by using selective pharmacological antagonists of nicotinic acetylcholine receptor subtypes it was shown that the ability of ghrelin to activate the cholinergic-dopaminergic reward link is mediated via specific subtypes of the nicotinic acetylcholine receptor, namely the α3β2*, α6* and β3* ).
Interestingly, these subtypes also mediate the rewarding properties of alcohol, alcohol cues as well as alcohol intake in rodents (Ericson et al. 2009; Jerlhag et al. 2006b; Larsson and Engel 2004; Löf et al. 2007; Steensland et al. 2007) . These data are verified in clinical tests; thus blocking these subtypes, by using varenicline, reduces the intake of alcohol in heavy drinking smokers (McKee et al. 2009 ) and one haplotype of the α6* gene is associated with heavy alcohol use ). Furthermore, it has M a n u s c r i p t 10 been shown that excessive alcohol intake in rats consuming alcohol for a long period of time causes a release of acetylcholine in the VTA followed by an increase in accumbal dopamine levels, showing that alcohol like ghrelin activates the cholinergicdopaminergic reward link (Larsson et al. 2005) . Taken together, there appears to be neurochemical analogies and overlaps between ghrelin and alcohol, where the cholinergic-dopaminergic reward link is the common denominator.
The activity of dopaminergic neurons in the VTA are mediated via various afferents and within the VTA GHS-R1A is present, not only on the dopaminergic cells, but also on presynaptic afferents (Abizaid et al. 2006 ) that could mediate the ability of ghrelin to activate the reward systems. Specifically, it has been found that the ability of ghrelin to increase the locomotor activity, accumbal dopamine release and condition a place preference (ie associate reward with a ghrelin-paired environment) was attenuated by a non-selective glutamate NMDA receptor antagonist (AP5) ).
Supportively, the ability of ghrelin to increase the electrical activity of dopaminergic neurons in the VTA appears to be dependent on the excitatory glutamatergic input, and also blockade of NMDA receptors in the VTA reduces food-induced accumbal dopamine release (Abizaid et al. 2006; Taber and Fibiger 1997) . Furthermore, NMDA receptors have also been shown to mediate the accumbal dopamine release observed when animals consume food after ghrelin administration (Kawahara et al. 2009 ). By contrast,
we were unable to demonstrate effects of either an opioid receptor antagonist or an orexin receptor A antagonist on the ability of ghrelin to activate the mesolimbic Page 11 of 38 A c c e p t e d M a n u s c r i p t 11 dopamine system . Albeit, central orexin signalling is important for ghrelin-induced food intake and for appetitive behaviour for high fat feeding (Perello et al. 2010; Toshinai et al. 2003) , implying that the ghrelin-induced reward versus ghrelininduced food intake are regulated, at least in part, via different mechanisms. Given that the plasma levels of ghrelin are elevated in association with addictive behaviours (see below), future therapeutic targets for these disorders may include agents such as nicotinic acetylcholine receptor or glutamate receptor antagonists acting at the level of the cholinergic-dopaminergic reward link.
The central ghrelin signalling system is required for reward from drugs of abuse, including alcohol.
Alcohol dependence, one of the major causes of death, is a chronic relapsing disease and is also a major cost for the society. Available treatments include medical, psychosocial as well as social interventions, which may help to increase time to relapse and to reduce the intake of alcohol. Alcohol dependence is a heterogeneous disorder where several signalling systems play important roles. By understanding the complex mechanisms underlying this disease new treatment strategies may be developed. While ghrelin was gaining status as a circulating hunger hormone, the work pinpointing the midbrain dopamine system as a target for ghrelin, led us to hypothesise that this system may have a role that extends beyond regulation of food intake and of energy balance homeostasis to include reward seeking behaviour, not only for rewarding foods but also for other reward reinforcers such as alcohol and other drugs of abuse. Interestingly, we A c c e p t e d M a n u s c r i p t 12 have now shown that ghrelin and its receptor have a role in drug-induced reward and specifically in alcohol dependence.
With regard to GHS-R1A, we showed that suppression of the GHS-R1A, using pharmacological or genetical approaches, reduces the rewarding properties of alcohol as measured by locomotor activity, accumbal dopamine release and conditioned place preference (ie associate reward with an alcohol-paired environment) in mice. Moreover, central or peripheral administration of the GHS-R1A antagonists (BIM28163 or JMV2959 respectively) reduces the intake of alcohol in mice consuming moderate amounts of alcohol ). These findings were later independently verified in studies showing that a GHS-R1A antagonist (D-Lys3-GHRP-6) reduces the intake of alcohol in mice (Kaur and Ryabinin 2010) . The GHS-R1A antagonist (JMV2959) has also been found to reduce the intake of alcohol using the intermittent alcohol consumption paradigm as well as operant self-administration model in high alcohol-preferring rats (Landgren et al. 2011) . Given that the GHS-R1A regulates the intake and reward from alcohol, the question arose regarding the extent to which the central ghrelin signalling system could be important for reinforcement from other drugs of abuse. Thus, peripheral administration of a GHS-R1A antagonist attenuates the rewarding properties of amphetamine and cocaine as measured by locomotor stimulation, accumbal dopamine release and conditioned place preference (Jerlhag et al. 2010a) . Clinical data also suggest a role for the GHS-R1A in regulating the intake of addictive drugs. Thus associations between one single SNP and haplotypes in the GHS-R1A gene and alcohol
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The endogenous peptide ghrelin also appears to have a role in drug-induced reward.
Specifically, ghrelin administration (icv or into the LDTg or VTA) increases the intake of alcohol in mice and the ability of alcohol to induce a locomotor stimulation, accumbal dopamine release and to condition a place preference is reduced in ghrelin knockout mice ). These effects are most likely mediated at the level of the cholinergic-dopaminergic reward link since hypothalamic administration of ghrelin does not influence the intake of alcohol in rats (Schneider et al. 2007) . Moreover, the effect of ghrelin is more pronounced in rodents exposed to alcohol since peripheral ghrelin administration to alcohol naïve rats only slightly increases the alcohol intake (Lyons et al. 2008) . Additionally, ghrelin augments cocaine-induced reward as measured by locomotor activity and conditioned place preference, and elevated ghrelin levels are associated with cocaine-seeking in rats (Davis et al. 2007; Tessari et al. 2007; Wellman et al. 2005) . Food restriction, that increases ghrelin levels (Gualillo et al. 2002) , augments cocaine-as well as amphetamine-induced locomotor stimulation, enhances cocaineseeking behaviour and increases the self-administration of cocaine or amphetamine in rats (Carroll et al. 1979) . In human genetic studies a ghrelin gene haplotype has been associated with paternal heredity of alcohol-use disorder (Landgren et al. 2010 ) and with increased weight in alcohol dependent individuals (Landgren et al. 2008) . After drinking alcohol the plasma levels of ghrelin decrease in healthy controls (Calissendorff Zimmermann et al. 2007) which is a similar effect to the reduced plasma levels of ghrelin post-prandially (Tschöp et al. 2001) . The relationship between plasma ghrelin levels and alcohol dependence in humans is somewhat unclear, where some studies show increased whereas some show decreased levels of ghrelin (Addolorato et al. 2006; Badaoui et al. 2008; Hillemacher et al. 2007; Kim et al. 2005; Kraus et al. 2005) . These apparent deviant results may depend on the heterogeneity of the disease and also on the time frame when the samples have been taken. Thus, it has been shown that ghrelin increases during the initial phase of abstinence but does not differ from healthy controls later during abstinence (Wurst et al. 2007) , and that elevated ghrelin levels are associated with craving during alcohol abstinence (Addolorato et al. 2006 ) (for review see Leggio 2010) .
Collectively these clinical and preclinical findings suggest that ghrelin as well as the GHS-R1A may regulate both the intake of and search for rewarding substances, and implies that treating patients with alcohol dependence with pharmacological agents interfering with the central ghrelin signalling system may have beneficial effects.
The central ghrelin signalling system is required for reward from food
In normal physiology, it seems likely that ghrelin does indeed operate as a circulating hunger hormone, conferring information to the brain about energy deficit and then interacting with key brain circuits to manifest a coordinated feeding response. This is achieved, in part, through activation of the aforementioned hypothalamic and . Peripheral ghrelin appears to enhance sweet taste food consumption and preference, regardless of its caloric content (Disse et al. 2010) . Direct administration of ghrelin into the brain ventricles or into the VTA stimulates food intake, of both normal chow and palatable food (Abizaid et al. 2006; Egecioglu et al. 2010; Naleid et al. 2005; Skibicka et al. 2011a ). Indeed, the fact that ghrelin can achieve this even in satiated M a n u s c r i p t 16 animals suggested that the VTA is an important site for ghrelin's orexigenic effects.
Consistent with this, we found that central intraventricular (Skibicka et al. 2011a ) or intra-VTA (Skibicka et al. 2011b ) injection of ghrelin to satiated rats increased motivation for a sucrose reward, assessed in an operant conditioning paradigm. In these studies animals show motivated behaviour by working increasingly hard (pressing a lever) to obtain a sweet treat. Thus, exogenous ghrelin not only initiates food intake but also, through enhancing motivated behaviour for rewarding food, enhances feeding behaviour and the amount of food consumed.
The orexigenic and adipogenic effects of ghrelin can be suppressed by ghrelin antagonists (Asakawa et al. 2003; Esler et al. 2007; Salomé et al. 2009a; Salomé et al. 2009b ). One week peripheral treatment of rats with the GHS-R1A antagonist, JMV2959, suppressed preference for palatable/rewarding food, and they did not gain as much weight as the vehicle-treated control rats (Egecioglu et al. 2010) . In this study, the ability of rewarding sweet treats to condition a place preference was also suppressed by the antagonists. In this powerful test of reward, the animals no longer show preference for the food (sweet treat)-paired environment, suggesting that the GHS-R1A antagonists suppress food reward. Moreover, we found that motivated behaviour for food reward can also be suppressed by intra-ventricular or intra-VTA administration of JMV2959 (Skibicka et al. 2011a; Skibicka et al. 2011b ). Thus, as reviewed elsewhere (Egecioglu et al. 2011; Skibicka and Dickson 2011) , GHS-R1A provides a potential target for the treatment of problematic over-eating. Indeed, it will be important to establish how the Page 17 of 38 A c c e p t e d M a n u s c r i p t 17 ghrelin-responsive circuits adapt during the development of diet-induced obesity (Lindqvist et al. 2005; Briggs et al. 2010) , and whether GHS-R1A antagonists could provide an effective therapy for this disease area.
The emerging neurobiology of central ghrelin signalling indicates that it may serve as a common denominator to enhance motivated behaviour for natural and artificial reward. Moreover, different pro-ghrelin gene polymorphisms have been linked to obesity, and to bulimia nervosa purging individuals (Ando et al. 2006; Gueorguiev et al. 2002; Korbonits et al. 2002; Ukkola et al. 2001; Vivenza et al. 2004; Vartiainen et al. 2006 ) as well as methamphetamine withdrawal ).
Thus, GHS-R1A emerges as a potential therapeutic target to suppress food reward and motivated behaviour for food, with possibilities for treating eating disorders that lead to obesity, especially those for which a dysfunctional reward system have been implicated (eg binging behaviour, compulsive over-eating).
Conclusions
The exact circuitry and mechanisms through which ghrelin modulates the intake and seeking of rewards remains to be further elucidated, but likely involves actions at the level of the cholinergic-dopaminergic reward system. GHS-R1A is expressed pre-and post-synaptically in the VTA (Abizaid et al. 2006) as well as on cholinergic neurons in the LDTg (Dickson et al. 2010) . Ghrelin injection into these discrete brain regions increases accumbal dopamine (Jerlhag et al. 2007 ) increases alcohol intake and food intake as well as motivated behaviour for palatable foods (Egecioglu et al. 2010; Skibicka et al. 2011b) . Indeed, pharmacological manipulations within the VTA reduce reward induced by ghrelin, additive drugs as well as for palatable food (Egecioglu et al. 2010; Jerlhag et al. 2009; Jerlhag et al. 2010a; Skibicka et al. 2011b ).
Page 19 of 38
A c c e p t e d M a n u s c r i p t
19
Extensive literature, as discussed herein, shows that suppression of central ghrelin signalling attenuates natural as well as chemical reinforcement as well as seeking for rewards. We suggest that the central ghrelin signalling system alters the set point of the dopaminergic neurons in the VTA and thereby enhances the ability of reward reinforcers such as food, alcohol or addictive drugs, to activate the midbrain dopamine reward system. It remains to be determined whether it is ghrelin itself that provides the signal to enhance the reward mechanism as the ghrelin receptor, GHS-R1A, has constitutive activity in absence of ligand (Holst et al. 2003) . Perhaps the GHS-R1A is regulated independently of ghrelin, for example, via heterodimerization to the dopamine D1-like receptor (Jiang et al. 2006 ). Interestingly, a role for D1 receptors in mediating alcohol intake, preference and oral self-administration in rodents has been found (Dyr et al. 1993; El-Ghundi et al. 1998 ). It is not yet known how the dopamine D1 receptor influences central ghrelin signalling and the physiological relevance of this dimerization remains to be determined.
Interestingly, there appears to be co-morbidities between eating disorders (specifically binge eating) and drug dependence (eg Anzengruber et al. 2006; Bulik 1991) and human imaging studies reveal an underlying disruption in the reward systems in addictive behaviours, including alcohol use disorder and binge eating Volkow and Li 2004 ). Therefore we suggest that similar mechanisms may play a role in multiple addictions and that central ghrelin signalling at the level of the cholinergic-dopaminergic M a n u s c r i p t 20 reward link play an important role. Indeed, SNPs and haplotypes of both the pro-ghrelin and GHS-R1A genes have been associated with increased weight in alcohol dependent individuals (Landgren et al. 2008) . Central ghrelin signalling has over the last years been shown to mediate the reward from alcohol Jerlhag et al. 2010b ), cocaine, amphetamine (Jerlhag et al. 2010a; Wellman et al. 2005; Tessari et al. 2007) , and palatable/rewarding food (Egecioglu et al. 2010; Perello et al. 2010; Skibicka et al. 2011a; Skibicka et al. 2011b) . Collectively these studies imply that central ghrelin signalling, including the GHS-R1A may constitute a novel target for development of treatment strategies for addictive behaviours. 
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